Melanoma-specific CD8+ T cell receptor (TCR)

Melanoma-specific CD8+ T cell receptors (TCRs) are alpha-beta heterodimeric surface proteins that enable cytotoxic T cells to recognize and eliminate melanoma cells by binding to specific tumor-associated antigens (TAAs) presented on Major Histocompatibility Complex (MHC) Class I molecules (NCI, 2023). These receptors target a variety of antigens, including lineage-specific proteins like MART-1 and gp100, or cancer-testis antigens such as NY-ESO-1 and MAGE-A4 (PubMed, 2021). In therapeutic applications, TCRs are either harnessed through tumor-infiltrating lymphocyte (TIL) therapy or engineered into peripheral blood T cells (TCR-T therapy) to redirect immune specificity toward the tumor (Nature Reviews Clinical Oncology, 2022). Upon binding to the peptide-MHC complex, the TCR initiates a signaling cascade through the CD3 complex, leading to the secretion of perforin, granzymes, and cytokines like IFN-gamma and TNF-alpha, which induce tumor cell apoptosis (Frontiers in Immunology, 2020). Therapeutic agents like Tebentafusp utilize a soluble TCR fused to an anti-CD3 scFv to bridge T cells and melanoma cells, while cell therapies like Afamitresgene autoleucel provide a direct cellular attack (FDA, 2024). Despite their efficacy, these targets pose risks of on-target, off-tumor toxicities, particularly when the target antigen is expressed in healthy tissues like the skin or uvea (Journal of Clinical Oncology, 2021).

Other names

Melanoma-associated antigen-specific T-cell receptorMART-1 specific TCRgp100 specific TCRNY-ESO-1 specific TCRMAGE-A4 specific TCRTumor-infiltrating lymphocyte receptor

Melanoma-specific CD8+ T cell receptors recognize specific melanoma-associated antigen peptides presented by MHC Class I molecules, triggering T cell activation and the release of cytotoxic granules that induce tumor cell apoptosis (PubMed, 2022).